REVIEW

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | 3 |  |  |  | 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  | 5 |  | 6 |  |  |  |  |  |  |  |  |  | 7 |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  | 8 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  | 9 |  |  |  |  | 10 |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  | 11 |  |  |  |  |  |  | 12 |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | 13 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  | 14 |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

|  |  |
| --- | --- |
| **Across****4.** CLEAR LIQUID IN WHICH THE DRUG IS COMPLETELY DISSOLVED **5.** REDUCING PARTICLE SIZE OF A SUBSTANCE BY GRINDING **8.** THE STRENGTH OF ACTIVE PHARMACUETICAL INGREDIENT IN A MED.**9.** THE PART OF THE WORD THAT IDENTIFYS THE MAJOR MEANING **10.** HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT (ABBR) **11.**  A DRUG THAT HAS BEEN MISLEADINGLY OR FRAUDENTLY LABELED **13.** LIQUID PREPARATION THAT CONTAINS INSOLUBLE PARTICLES **14.** AMOUNT OF MED. PRESCRIBED TO BE TAKEN AT ONE TIME  | **Down****1.** THE SHARP POINTED END OF A NEEDLE **2.** LISTS TYPES OF PATIENT WHO SHOULD NOT USE THE DRUG**3.** PROCESS OF TRANSFORMING DRUGS IN THE BODY **6.** CONTAINING THE SAME TONICITY AS RED BLOOD CELLS **7.** ORAL FORM THAT DISINTEGRATES OVER TIME **12.**  REGULATES THE LEGAL TRADE IN CONTROLLED DRUGS  |

   MISBRANDED       DEA       CONTRAINDICATIONS       ROOT       HIPPA       TRITURATION       TROCHE       SUSPENSION       SOLUTION       ISOTONIC       BEVEL       DOSE       CONCENTRATION       METABOLISM